Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

672

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab 200 mg
BIOLOGICAL: Pembrolizumab 400 mg
DRUG: Pembrolizumab placebo (saline)
DRUG: Pembrolizumab placebo (saline)
DRUG: Olaparib 300 mg BID
DRUG: Olaparib matching placebo
DRUG: Etoposide 100 mg/m^2
DRUG: Platinum, investigator's choice
RADIATION: Standard Thoracic Radiotherapy
RADIATION: Prophylactic Cranial Irradiation (PCI)

Sponsor

Merck Sharp & Dohme LLC